Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sihuan Pharmaceutical and dProtein Biotechnology Form AI-Powered Medical Aesthetics Joint Venture

Fineline Cube May 29, 2026
Company Deals Drug

Salvectors Receives NMPA Clinical Approval for YB1-X7, World’s First Oncolytic Salmonella Therapy for Advanced Solid Tumors

Fineline Cube May 29, 2026
Company Deals

Kexing Pharmaceutical and Sinotherapeutics Partner to Commercialize Tofacitinib Extended-Release Tablets in Kuwait and Mexico

Fineline Cube May 29, 2026
Company Deals

Genrix Bio Licenses BCMA×CD3 Bispecific Velinotamig to Fosun’s Yaopharma for Greater China in $268M Deal

Fineline Cube May 29, 2026
Company Deals

Innovent Biologics and Pfizer Forge $10.5B Global Oncology Partnership Spanning 12 First-in-Class Programs

Fineline Cube May 29, 2026
Policy / Regulatory

China’s NHSA Proposes First National Basic Medical Insurance Medical Service Items List to Standardize Reimbursement Framework

Fineline Cube May 29, 2026
Company Drug

Sanofi’s Venglustat Receives FDA Priority Review and Breakthrough Therapy Designation for Type 3 Gaucher Disease

Fineline Cube May 29, 2026
Company Drug

BeOne Medicines and Amgen’s Tarlatamab Receives NMPA Conditional Approval for Second-Line ES-SCLC in China

Fineline Cube May 29, 2026
Company Drug

Alphamab Oncology Highlights KN046, KN026 Advances at ESMO 2022

Fineline Cube Sep 5, 2022

China’s Alphamab Oncology (HKG: 9966) will present updated clinical data for its bispecific antibody candidates...

Company Drug

AstraZeneca’s Farxiga Wins China Approval for Chronic Kidney Disease

Fineline Cube Sep 5, 2022

UK pharma giant AstraZeneca (AZ, NASDAQ: AZN) announced a new approval for Farxiga (dapagliflozin), its...

Company Drug

Innovent Biologics Doses First Patient in Higher-Dose Mazdutide Obesity Trial

Fineline Cube Sep 5, 2022

China’s Innovent Biologics, Inc. (HKG: 1801) announced that the first participant has been dosed in...

Company Drug

Shanghai Pharma’s CD20 Antibody Advances to Primary Nephropathy Trial After NMPA Approval

Fineline Cube Sep 5, 2022

China’s Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) has received approval from the National Medical Products...

Company Drug

Walvax Biotech Wins NMPA Approval for mRNA and Recombinant COVID-19 Vaccines

Fineline Cube Sep 2, 2022

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has received clinical trial approvals from the National...

Company Deals

Medim Science Raises Funds for Macrophage-Targeting Biologics in Cancer Therapy

Fineline Cube Sep 2, 2022

Hangzhou-based Medim Science, China’s first pharma firm focused on macrophage-targeting biologics, has reportedly raised tens...

Drug Medical Device

China’s Pharmaceutical Industry Sees Revenue Decline Amid Export Shifts

Fineline Cube Sep 2, 2022

China’s pharmaceutical manufacturing sector reported a 1.8% year-on-year (YOY) revenue decline to RMB 1.6 trillion...

Company Deals

Tibet Duo Rui and Nanjing Heron Forge Pharmaceutical Collaboration in China

Fineline Cube Sep 2, 2022

China-based Tibet Duo Rui Pharmaceutical Co., Ltd and Nanjing Heron Pharmaceutical Science and Technology Co.,...

Company Drug

CARsgen Therapeutics Launches GMP Manufacturing for CAR-T Cell Therapies in North Carolina

Fineline Cube Sep 2, 2022

China’s CARsgen Therapeutics Holdings Ltd (HKG: 2171), a chimeric antigen receptor (CAR)-T cell specialist, has...

Company Deals

MegaRobo and Danaher Life Sciences Partner on Lab Automation in China

Fineline Cube Sep 2, 2022

Beijing-based MegaRobo Technologies, a robotics and AI firm in life sciences, has partnered with Danaher...

Company Drug

Hengrui Medicine’s HRG2101 Inhaler Wins NMPA Approval for IPF Clinical Trial

Fineline Cube Sep 2, 2022

China’s Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has received approval from the National Medical...

Company Deals

U Protech Secures Angel Financing for PROTAC and Molecular Glue Drug Pipeline

Fineline Cube Sep 2, 2022

U Protech, a Hangzhou-based biotech focused on next-generation protein degradation therapies, has raised tens of...

Company Deals Digital

J&J China, Tencent Launch Digital Rhinitis Platform “Love Nose e-Station”

Fineline Cube Sep 2, 2022

Johnson & Johnson’s (J&J, NYSE: JNJ) J&J China Self Care and China’s Tencent have launched...

Company Deals

Neukio Biotherapeutics Completes USD 50M Series A-1 Financing for iPSC-CAR-NK Therapy

Fineline Cube Sep 2, 2022

Shanghai-based Neukio Biotherapeutics, a developer of iPSC-derived chimeric antigen receptor natural killer (CAR-NK) cell therapies,...

Company Deals

Acorda Therapeutics Licenses Preclinical Drug Nepicastat to China’s Asieris

Fineline Cube Sep 2, 2022

US-based Acorda Therapeutics Inc. (Nasdaq: ACOR) announced a licensing agreement with China’s Asieris Pharmaceuticals for...

Policy / Regulatory

SAMR Issues New Rules for Online Drug Sales in China

Fineline Cube Sep 2, 2022

China’s State Administration for Market Regulation (SAMR) has released the “Measures for the Supervision and...

Policy / Regulatory

NMPA Designates Shijiazhuang Airport as Drug Import Port for Narcotics, Psychotropics

Fineline Cube Sep 2, 2022

China’s National Medical Products Administration (NMPA) has designated Shijiazhuang Airport in Hebei Province as an...

Company

Henlius Biotech Plans US Bridging Study for Serplulimab in ES-SCLC

Fineline Cube Sep 1, 2022

Shanghai Henlius Biotech (HKG: 2696) is advancing its checkpoint inhibitor serplulimab toward the U.S. market,...

Company Drug

RedCloud Bio Doses First Patient in H002 EGFR TKI Phase I/IIa Trial for NSCLC

Fineline Cube Sep 1, 2022

Shanghai-based RedCloud Bio announced that the first patient has been dosed in a Phase I/IIa...

Company Drug

Lepu Biopharma’s MRG002 Earns FDA Orphan Drug Status for Gastric Cancer

Fineline Cube Sep 1, 2022

China’s Lepu Biopharma Co., Ltd (HKG: 2157) announced that the U.S. FDA has granted orphan...

Posts pagination

1 … 637 638 639 … 674

Recent updates

  • Sanofi’s Venglustat Receives FDA Priority Review and Breakthrough Therapy Designation for Type 3 Gaucher Disease
  • BeOne Medicines and Amgen’s Tarlatamab Receives NMPA Conditional Approval for Second-Line ES-SCLC in China
  • Northland Biotech’s Engensis Gene Therapy Receives NMPA Approval for Severe Lower Limb Ischemia Ulcers
  • AstraZeneca’s Fasenra Becomes First Biologic Approved in China for Hypereosinophilic Syndrome
  • Shionogi’s Symproic (Naldemedine) Receives NMPA Approval for Opioid-Induced Constipation in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sanofi’s Venglustat Receives FDA Priority Review and Breakthrough Therapy Designation for Type 3 Gaucher Disease

Company Drug

BeOne Medicines and Amgen’s Tarlatamab Receives NMPA Conditional Approval for Second-Line ES-SCLC in China

Company Drug

Northland Biotech’s Engensis Gene Therapy Receives NMPA Approval for Severe Lower Limb Ischemia Ulcers

Company Drug

AstraZeneca’s Fasenra Becomes First Biologic Approved in China for Hypereosinophilic Syndrome

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.